J
Jan Davis
Researcher at University of Texas MD Anderson Cancer Center
Publications - 6
Citations - 1048
Jan Davis is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Decitabine & Chronic myelomonocytic leukemia. The author has an hindex of 5, co-authored 6 publications receiving 989 citations. Previous affiliations of Jan Davis include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop M. Kantarjian,Yasuhiro Oki,Guillermo Garcia-Manero,Xuelin Huang,Susan O'Brien,Jorge E. Cortes,Stefan Faderl,Carlos E. Bueso-Ramos,Farhad Ravandi,Zeev Estrov,Alessandra Ferrajoli,William G. Wierda,Jianqin Shan,Jan Davis,Francis J. Giles,Hussain I. Saba,Jean Pierre J. Issa +16 more
TL;DR: It is concluded that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS.
Journal ArticleDOI
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Hagop M. Kantarjian,Varsha Gandhi,Jorge E. Cortes,Srdan Verstovsek,Min Du,Guillermo Garcia-Manero,Francis J. Giles,Stefan Faderl,Susan O'Brien,Sima Jeha,Jan Davis,Zeev Shaked,Adam R. Craig,Michael J. Keating,William Plunkett,Emil J. Freireich +15 more
TL;DR: Clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance.
Journal ArticleDOI
Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.
Guillermo Garcia-Manero,Hui Yang,Blanca Sanchez-Gonzalez,Srdan Verstovsek,Alessandra Ferrajoli,Michael J. Keating,Michael Andreeff,Susan O'Brien,Jorge E. Cortes,William G. Wierda,Stefan Faderl,Charles Koller,Jan Davis,Gail Morris,Jean Pierre J. Issa,Stanley R. Frankel,Victoria M. Richon,Bernard Fine,Hagop M. Kantarjian +18 more
TL;DR: The MTD of oral vorinostat is either 200mg po TID or 200 mg po BID x 14 days every 21 days in patients with leukemia, and this single agent activity warrants additional investigation of the role of vorInostat in the therapy of AML.
Journal ArticleDOI
Decitabine Low-Dose Schedule (100 mg/m2/course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.
Hagop M. Kantarjian,Farhad Ravandi,Susan O'Brien,Francis J. Giles,Stefan Faderl,Guillermo Garcia-Manero,Jan Davis,Elihu H. Estey,Jean Pierre J. Issa +8 more
TL;DR: Decitabine at this low-dose schedule has major anti- MDS activity in the setting of poorer risk MDS; 2) the optimal dose schedule is being defined; 3) side effects are acceptable; 4) timely and repeated courses of decitabines are required for optimal response results.
Journal ArticleDOI
A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes
Guillermo Garcia-Manero,Stefan Faderl,Francis J. Giles,Deborah A. Thomas,Jorge E. Cortes,Susan O'Brien,Jan Davis,Hagop M. Kantarjian,Elihu H. Estey +8 more
TL;DR: The addition of amifostine does not allow dose escalation of idarubicin when combined with high-dose ara-C, and is shown to protect against the acute cytotoxicities of anthracyclines in animal models.